CAPTRUST Financial Advisors
MGRX icon

CAPTRUST Financial Advisors’s Mangoceuticals MGRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,138
Closed -$4.03K – 2358
2024
Q3 		$4.03K Buy
+1,138
New +$5.37K ﹤0.01% 2284

Other funds holding MGRX

ACA
Ackerman Capital Advisors Dallas, Texas $488M AUM 14.36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAPTRUST Financial Advisors's MGRX Position: Q4 2024 in Review

CAPTRUST Financial Advisors sold out of Mangoceuticals (MGRX) in Q4 2024, closing a stake of 1,138 shares — an estimated $4.03K sold.

CAPTRUST Financial Advisors first reported a position in MGRX in Q3 2024 and held it in 1 quarter. The position peaked at $4.03K in Q3 2024. 9 funds tracked by Wall St. Rank hold MGRX as of Q4 2024.

  • CAPTRUST Financial Advisors reported no remaining Mangoceuticals position as of Q4 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,138 Mangoceuticals shares in Q4 2024, an estimated $4.03K.
  • CAPTRUST Financial Advisors first reported a position in Mangoceuticals in Q3 2024 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Mangoceuticals position peaked at $4.03K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Mangoceuticals as of Q4 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.